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Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62 S43Results: Among the genes that were strongly upregulated on all 3 time
points after induction of CIOA were MMP-3 (6-fold), MMP-13 (16-fold),
MMP-14 (6-fold). Wound healing, phagocytosis, chemotaxis and met-
alloproteases were signiﬁcantly enriched, as were the complement
pathway, the TLR-, TGFb, BMP and wnt-signaling pathways. Highly
similar results were obtained in the DMM model for OA. However, at
day 42 in this model very view genes were still regulated in the syno-
vium compared to other time points or CIOA, indicating that synovial
activation differs late between the models. This was underlined by
histological examination, that shows thickened synovial lining mainly
in CIOA. All in all, the expression patterns in experimental OA showed
compelling similarities with human OA synovium. Gene expression
proﬁles of control synovia were compared to CHECK synovia. Analysis
using DAVID indicated enrichment of several biological processes and
signaling pathways, including macrophage presence, cell migration,
TGFb-, BMP- and wnt-signaling. This indicates clear activation of the
synovium in the CHECK patients compared to controls. Next we
compared synovial tissue of CHECK-patients with radiological damage
(KL1) with CHECK-patients without joint damage (KL¼0). In the top
30 genes that were associated with cartilage damage were MMP-1 (18-
fold), MMP-3 (10-fold) and S100A8 (6-fold), all of which have been
associated with cartilage damage. FAC analysis further underlined
response to wounding, chemotaxis, innate immune response and
metalloproteases to be strongly enriched. In particular, complement-
activation pathway, TGFb- and BMP-signaling and TLR-activation were
striking.
Conclusions: Activation pathways and processes in the two models for
OA were highly similar. A major difference lies in the presence of late
synovial activation. This may direct the choice for the most optimal
model to study certain OA subpopulations, since this difference was
obvious in human OA, where roughly 50% shows marked synovitis. The
FAC data suggest an active role for the synovium in OA pathology, and
identiﬁes pathways likely to be involved. One of the strongest associ-
ations was of the complement-pathway with cartilage damage. In
addition, synovial MMP expression was associated with cartilage
damage, underlining an active role of synovium in OA pathology.69
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Purpose: Osteophytes are signs of osteoarthritis (OA) that develop from
proliferating mesenchymal stem cells (MSCs) as bony outgrowths at the
margins of the joint. The synovium is one source of MSCs that can be
induced to undergo chondrogenesis and applied to regenerate articular
cartilage defects. Perlecan is a heparan sulfate proteoglycan present in
all basementmembranes and in the extracellular matrix of cartilage and
synovium. Perlecan interacts with other extracellular matrix proteins,
growth factors and receptors, and is implicated in cell growth, differ-
entiation, signaling, and stem cell maintenance.
We demonstrated that synovial perlecan is required for osteophyte
formation in a surgical OA model and a TGF-b-induced model using
perlecan-knockout mice (Hspg2-/--Tg) that we rescued from perinatal
lethality by transgenic perlecan expression in cartilage only (Ishijima et
al, Matrix Biology, 2012; Kaneko et al, OARSI 2011). We recently estab-
lished a primary mouse synovial cell culture method, in which mouse
synovial mesenchymal cells (SMCs) demonstrated both the ability to
proliferate andmulti-potentiality similar or superior to the cells derived
frommuscle or bonemarrow (Futami et al, PLOS One, 2012). The purpose
of the present study was to investigate the role of perlecan during
chondrogenic differentiation from synovial cells using established
primary mouse SMCs.
Methods: The primary SMCs were isolated by our established method
(Futami et al, PLOS One, 2012) from Hspg2-/--Tg and control Hspg2+/+-Tg
mice. To analyze cell growth kinetics, we plated synovial cells at passage4 at 1,000 cells/cm2 and cultured them for 14 days, counting cell
numbers with a hemocytometer every two days. We evaluated the
chondrogenic potential of SMCs in micromass cultures by both Alcian
blue staining and quantitative real-time PCR (qRT-PCR), performed in
RNA isolated at 3, 12, 72 hours, 1 and 2 weeks after chondrogenic
induction.
Results:We were able to isolate primary mouse SMCs from knee joints
of control and Hspg2-/--Tg mice. SMCs isolated from Hspg2-/--Tg mice
did not express perlecan, while those from control mice expressed
perlecan, as assessed by both immunohistochemical and qRT-PCR
analyses. SMCs cultures from control and Hspg2-/--Tg mice showed
similar proliferative potential in the absence of the chondrogenic
induction. However, during in vitro chondrogenic differentiation in
micromass culture, the cartilage matrix production detected by Alcian
blue staining in perlecan-deﬁcient SMCs was dramatically inhibited
compared to that in control SMCs. Accordingly, qRT-PCR analysis
demonstrated that the expression levels of Sox5, Sox9, Col2a1, Mmp13,
Adamts5, and Vegf mRNAs were also reduced during chondrogenic
differentiation in perlecan-deﬁcient SMCs compared to control SMCs.
Conclusions: This in vitro study showed that SMCs were viable and
proliferative, even in the absence of perlecan. On the other hand, when
SMCs were induced to undergo chondrogenesis, matrix production and
chondrogenic gene expressionwas impaired by the absence of perlecan.
Therefore, we conclude that perlecan is a prerequisite for chondrogenic
differentiation of SMCs.70
FACTORS ASSOCIATED WITH INCIDENT VARUS THRUST IN KNEE
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K.C. Moisio y, O. Olmagor y, J.S. Chmiel y, A. Chang y, K. Hayes y,
D. Dunlop y, J. Bathon z, C. Eaton x, M. Hochberg k, R. Jackson {,
K. Kwoh#, M. Nevitt yy, L. Sharma y. yNorthwestern Univ., Chicago, IL,
USA; z Johns Hopkins Univ., Baltimore, MD, USA; xBrown Univ.,
Pawtucket, RI, USA; kUniv. of Maryland, Baltimore, MD, USA; {Ohio
State Univ., Columbus, OH, USA; #Univ. of Pittsburgh, Pittsburgh, PA,
USA; yyUniv. of California, San Francisco, CA, USA
Purpose: Varus thrust can be visualized during gait as the dynamic
worsening or abrupt onset of varus alignment as the leg enters stance
phase, with a return to a more neutral alignment during toe-off and
swing phase. Varus thrust has been shown to be associated with a 4-
fold increase in the odds of medial tibiofemoral OA progression over an
18-month follow-up (Chang 2004). Varus thrust can develop at any
point during the disease process; factors associated with incident thrust
have not been identiﬁed. We hypothesized that varus alignment at
baseline is associated with incident varus thrust by 2 years later. In
addition to alignment, we sought to identify other baseline factors
associated with incident varus thrust, including: age, sex, BMI, race/
ethnicity, Physical Activity Scale for the Elderly (PASE) score, back pain
in past 30 days, previous knee injury limiting walking ability for 2
days, history of any knee surgery, knee extensor strength, and disease
severity.
Methods: The Osteoarthritis Initiative (OAI) is a prospective observa-
tional cohort study of incident and progressive knee OA. Observational
gait analysis by trained examiners at baseline (12 month) and 2 years
later (36 month visit) was used to assess varus thrust presence in OAI
participants. We categorized: BMI as normal (<25 kg/m2), overweight
(25-29.9), obese (30); race as White, African American, or other; knee
alignment as varus (deﬁned as>1 in the varus direction) or non-varus;
and disease severity as K/L 0-1, 2, or 3-4. To assess the relationship
between baseline factors and incident thrust by 2 years later, we used
multivariable logistic regression with GEE. The ﬁnal model was derived
using a backwards selection process that retained variables with p<0.2
from the initial full model with all baseline factors. Results are reported
as adjusted odds ratios (ORs) and 95% conﬁdence intervals (CIs); CIs that
exclude 1.0 are signiﬁcant at the 5% level.
Results: The sample included 4399 knees from 2909 persons [mean age
62 yrs ( 9, SD), BMI 28 kg/m2 (5), 59% women] who did not have
a varus thrust in either knee at baseline. At 2 years, 835 knees exhibited
a varus thrust. Age, knee injury, surgery, extensor strength, and PASE
did not meet criteria for inclusion in the ﬁnal model. The Table shows
the adjusted OR (95% CI) for each variable in the ﬁnal model. Varus
alignment, male sex, back pain, obese BMI (vs. normal BMI), and K/L
grades 2 and 3-4 (vs. K/L 0-1) were independently associated with an
